-+ 0.00%
-+ 0.00%
-+ 0.00%

BridgeBio Oncology Therapeutics Q3 2026 Net Loss Narrows 24% to $34.2 Million

PUBT·11/10/2026 21:35:55
Listen to the news
BridgeBio Oncology Therapeutics Q3 2026 Net Loss Narrows 24% to $34.2 Million
  • BridgeBio Oncology Therapeutics’ third-quarter 2026 net loss narrowed 24% year over year to $34.2 million.
  • Research and development expenses fell 16% to $29.6 million, while general and administrative expenses dropped 44% to $7.9 million.
  • Cash, cash equivalents and marketable securities totaled $315.3 million at September 30, with runway expected into 2029.
  • BBO-8520 with pembrolizumab achieved a 75% objective response rate at 500 mg daily in KRASG12C inhibitor-experienced non-small cell lung cancer patients.
  • Monotherapy data updates for BBO-11818 and BBO-10203 are expected in the fourth quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-455506), on November 10, 2026, and is solely responsible for the information contained therein.